Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Moderna
MRNA
|
$1.79B |
| 2 |
Illumina
ILMN
|
$780M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$727M |
| 4 |
DexCom
DXCM
|
$453M |
| 5 |
Netflix
NFLX
|
$384M |
Top Sells
| 1 |
Tesla
TSLA
|
$5.22B |
| 2 |
Amazon
AMZN
|
$1.3B |
| 3 |
Alphabet (Google) Class C
GOOG
|
$610M |
| 4 |
Zillow
Z
|
$470M |
| 5 |
Ionis Pharmaceuticals
IONS
|
$271M |
Sector Composition
| 1 | Consumer Discretionary | 37.93% |
| 2 | Technology | 16.18% |
| 3 | Healthcare | 15.43% |
| 4 | Communication Services | 14.41% |
| 5 | Financials | 5.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
British American Tobacco
BTI
$122B
| $8.22M | ﹤0.01% |
219,238
+1,077
| +0.5% | +$40.4K |
|
227
Ascendis Pharma
ASND
$12.5B
| $7.87M | ﹤0.01% |
+47,155
| New | +$7.87M |
|
228
Fortive
FTV
$16.2B
| $7.74M | ﹤0.01% |
109,219
-64,811
| -37% | -$4.59M |
|
|
229
Ionis Pharmaceuticals
IONS
$9.76B
| $7.14M | ﹤0.01% |
126,218
-4,794,625
| -97% | -$271M |
|
|
SINA
230
DELISTED
Sina Corp
SINA
| $5.58M | ﹤0.01% |
131,550
| – | – |
|
231
Health Catalyst
HCAT
$238M
| $5.31M | ﹤0.01% |
122,053
+59,738
| +96% | +$2.6M |
|
|
BRW
232
Saba Capital Income & Opportunities Fund
BRW
$349M
| $4.96M | ﹤0.01% |
+555,105
| New | +$4.96M |
|
233
American Well
AMWL
$113M
| $4.73M | ﹤0.01% |
9,335
+4,550
| +95% | +$2.3M |
|
234
MRC Global
MRC
$1.28B
| $4.31M | ﹤0.01% |
650,000
| – | – |
|
|
KLDO
235
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $4M | ﹤0.01% |
440,000
| – | – |
|
236
Veeva Systems
VEEV
$44.7B
| $3.82M | ﹤0.01% |
+14,024
| New | +$3.82M |
|
|
VEDL
237
DELISTED
Vedanta Limited American Depostary Shares (Each representing four equity shares)
VEDL
| $3.79M | ﹤0.01% |
+431,984
| New | +$3.79M |
|
238
Relay Therapeutics
RLAY
$710M
| $3.32M | ﹤0.01% |
79,932
-5,584,989
| -99% | -$232M |
|
|
SOHU
239
Sohu.com
SOHU
$467M
| $3.19M | ﹤0.01% |
200,140
| – | – |
|
|
SAGE
240
DELISTED
Sage Therapeutics
SAGE
| $2.85M | ﹤0.01% |
32,916
+15,886
| +93% | +$1.37M |
|
241
Adicet Bio
ACET
$60M
| $2.55M | ﹤0.01% |
181,626
| – | – |
|
242
Korea Electric Power
KEP
$17.2B
| $1.96M | ﹤0.01% |
159,440
+5,460
| +4% | +$67K |
|
|
NSL
243
DELISTED
NUVEEN SENIOR INCM FD
NSL
| $1.95M | ﹤0.01% |
375,012
| – | – |
|
244
Alector
ALEC
$305M
| $1.85M | ﹤0.01% |
122,406
+58,548
| +92% | +$886K |
|
245
Summit Therapeutics
SMMT
$19.3B
| $1.75M | ﹤0.01% |
372,261
| – | – |
|
|
UXIN
246
Uxin Ltd
UXIN
$722M
| $1.55M | ﹤0.01% |
17,761
| – | – |
|
247
Vontier
VNT
$6.37B
| $1.53M | ﹤0.01% |
+45,779
| New | +$1.53M |
|
248
WEC Energy
WEC
$34.7B
| $1.22M | ﹤0.01% |
13,262
| – | – |
|
|
BLUE
249
DELISTED
bluebird bio
BLUE
| $1.01M | ﹤0.01% |
1,801
-52,785
| -97% | -$29.6M |
|
250
NextEra Energy, Inc.
NEE
$146B
| $930K | ﹤0.01% |
12,056
| – | – |
|